
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is well-positioned for growth in the rapidly evolving field of personalized cancer treatments, leveraging its strong partnerships with biopharmaceutical companies and a cash position of $261.3 million. Their success in securing Medicare coverage for their lung cancer test and efforts to expand coverage for other types of cancer reflect their potential for growth and profitability in the future. With their advanced technology and strong intellectual property strategy, Personalis is poised to capture a significant share of the estimated $35 billion market in this area.
Bears say
Personalis is anticipating growth in their biopharma and clinical diagnostics revenues, but investors should be wary of the volatility of budgets and ordering patterns with pharma companies. Additionally, the company's cross-licensing IP strategy with Myriad Genetics highlights potential IP risks they face in the ultra-sensitive MRD testing market. Furthermore, Tempus AI's financial situation raises concerns for their ability to generate enough revenue for future profitability.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares